Skip to content

Study the efficacy of risperidone in the treatment of persistent psychosis induced by methamphetamine

Study the efficacy of risperidone compared to placebo plus Electroconvulsive therapy in the treatment of persistent psychosis induced by methamphetamine in patients referred to Farabi hospital of Kermanshah

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130812014333N101
Enrollment
12
Registered
2018-09-18
Start date
2018-09-18
Completion date
Unknown
Last updated
2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphtamine induced psychotic disorder. Mental and behavioural disorders due to use of other stimulants, including caffeine

Interventions

Intervention 1: The first intervention group will receive 4 mg Risperidone (in two divided doses) daily for 4 weeks with a two-way frontotemporal ECT. Intervention 2: The second intervention group wil

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The presence of psychosis due to methamphetamine consumption despite discontinuation of methamphetamine for one month No history of previous psychiatric disorders such as schizophrenia and ..... No medical diseases that have psychosis symptoms such as brain tumors and ...

Exclusion criteria

Exclusion criteria: No persistent psychosis associated with methamphetamine abuse. The presence of recent cardiovascular disease based on the patient's history or cardiologist's opinion Sensitivity or side effects during treatment with risperidone. History or presence of primary psychosis

Design outcomes

Primary

MeasureTime frame
Severity of psychotic symptoms. Timepoint: At the beginning of the study, the second week and at the end of the study (4 weeks after the start of the study). Method of measurement: Based on the Positive and Negative Symptoms Scale (PANSS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdoll Reza Darki

Kermanshah University of Medical Sciences

darki121@yahoo.com+98 83 3826 1046

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026